Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
11(58%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
3
16%
Ph phase_1
4
21%
Ph phase_2
11
58%
Ph phase_3
1
5%

Phase Distribution

4

Early Stage

11

Mid Stage

1

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
11(57.9%)
Phase 3Large-scale testing
1(5.3%)
N/ANon-phased studies
3(15.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

11

trials recruiting

Total Trials

19

all time

Status Distribution
Active(12)
Completed(1)
Terminated(1)
Other(5)

Detailed Status

Recruiting10
unknown5
Completed1
Active, not recruiting1
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
11
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (21.1%)
Phase 211 (57.9%)
Phase 31 (5.3%)
N/A3 (15.8%)

Trials by Status

recruiting1053%
unknown526%
completed15%
active_not_recruiting15%
not_yet_recruiting15%
withdrawn15%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT06217757Phase 1

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Recruiting
NCT06732258Phase 1

Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Withdrawn
NCT06477523Phase 1

Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC

Active Not Recruiting
NCT05941741Phase 3

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

Recruiting
NCT07448142Phase 2

Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer

Recruiting
NCT07408609Phase 2

Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Not Yet Recruiting
NCT07371234Phase 2

Low-Dose Radiotherapy and Anti-PD-1 Immunotherapy as Neoadjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
NCT07312422Phase 1

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Recruiting
NCT06446726Phase 2

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Recruiting
NCT06494995Phase 2

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Recruiting
NCT06791148Phase 2

Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer

Recruiting
NCT05292027Not Applicable

Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Completed
NCT06220552Phase 2

The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma

Recruiting
NCT05092412Phase 2

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Unknown
NCT05343325Phase 2

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Recruiting
NCT05543070Phase 2

Low-dose Radiotherapy in iNHL

Unknown
NCT05503914Not Applicable

Low-dose Radiotherapy and Neoadjuvant Chemotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Unknown
NCT04380818Not Applicable

Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19

Unknown
NCT02803840Phase 2

Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma

Unknown

All 19 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
19